日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Recruitment of the multiple sclerosis cohort within the European Mobilise-D clinical validation study-lessons learnt, baseline demographics and clinical characteristics

欧洲 Mobilise-D 临床验证研究中多发性硬化症队列的招募——经验教训、基线人口统计学和临床特征

Brittain, Gavin; Buckley, Ellen; Lanfranchi, Vita; Long, Mike; Tsaktanis, Thanos; Rothhammer, Veit; Hansen, Clint; Stürner, Klarissa Hanja; Maetzler, Walter; Rochester, Lynn; Sutcliffe, Lou; Neatrour, Isabel; Vereijken, Beatrix; Buekers, Joren; Garcia-Aymerich, Judith; Koch, Sarah; Armengol, Claudia; Gassner, Heiko; Jansen, Carl-Philipp; Rooks, Daniel; Leocani, Letizia; Brichetto, Giampaolo; Costa, Gloria Dallas; Becker, Clemens; Comi, Giancarlo; Sharrack, Basil

Digital remote monitoring of people with multiple sclerosis

对多发性硬化症患者进行数字化远程监测

Dini, Michelangelo; Comi, Giancarlo; Leocani, Letizia

Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials

奥扎尼莫德治疗复发型多发性硬化症患者的脑萎缩及其与长期残疾和认知功能的关系:来自 3 期和开放标签扩展试验的结果

Cohen, Jeffrey A; Arnold, Douglas L; DeLuca, John; Hartung, Hans-Peter; Kappos, Ludwig; Comi, Giancarlo; Selmaj, Krzysztof; Steinman, Lawrence; Bar-Or, Amit; Montalban, Xavier; Havrdová, Eva K; Sheffield, James K; Pachai, Chahin; Cheng, Chun-Yen; Riolo, Jon V; Cree, Bruce Ac

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

奥扎尼莫德治疗复发型多发性硬化症的长期安全性和有效性:DAYBREAK开放标签扩展试验的最终分析

Selmaj, Krzysztof W; Steinman, Lawrence; Comi, Giancarlo; Bar-Or, Amit; Arnold, Douglas L; Hartung, Hans-Peter; Montalbán, Xavier; Havrdová, Eva K; Sheffield, James K; Krakovich, Anthony; Cheng, Chun-Yen; Riolo, Jon V; Pachai, Chahin; Thorpe, Andrew; DeBoer, Erik; Kappos, Ludwig; Cohen, Jeffrey A; Cree, Bruce Ac

Patient-Generated Data as Indicators of Impact of Multidisciplinary and Multi-stakeholder Health Care Systems, in the Age of Personalised Medicine

在个性化医疗时代,患者生成的数据可作为衡量多学科、多方利益相关者医疗保健系统影响的指标

Zaratin, Paola; Soelberg Sørensen, Per; Fernández, Óscar; Comi, Giancarlo

Development and validation of an electronic Symbol-Digit Modalities Test for remote monitoring of people with multiple sclerosis

开发和验证用于远程监测多发性硬化症患者的电子符号-数字模式测试

Dini, Michelangelo; Gamberini, Giulia; Tacchini, Marta; Boschetti, Angela; Gradassi, Alessandro; Chiveri, Luca; Rodegher, Mariaemma; Comi, Giancarlo; Leocani, Letizia

Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials

胶质纤维酸性蛋白作为复发型多发性硬化症的疾病标志物:Ozanimod III期试验的事后分析

Harris, Sarah; Comi, Giancarlo; Cree, Bruce A C; Arnold, Douglas L; Steinman, Lawrence; Sheffield, James K; Maddux, Rachel; Southworth, Harry; Kappos, Ludwig; Cohen, Jeffrey A

Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress

识别多发性硬化症髓鞘再生和恢复的生物标志物:衡量进展

Ricigliano, Vito A G; Marenna, Silvia; Borrelli, Serena; Camera, Valentina; Carnero Contentti, Edgar; Szejko, Natalia; Bakirtzis, Christos; Gluscevic, Sanja; Samadzadeh, Sara; Hartung, Hans-Peter; Selmaj, Krzysztof; Stankoff, Bruno; Comi, Giancarlo; Ecf Young Investigators/Fellows Initiative

Transcorneal Electrical Stimulation Modulates Visual Pathway Function in Mice

经角膜电刺激调节小鼠视觉通路功能

Castoldi, Valerio; Rossi, Elena; Marenna, Silvia; Comi, Giancarlo; Leocani, Letizia

RECLAIM-A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis

RECLAIM——一项回顾性多中心观察性研究,旨在开发人工智能驱动的多发性硬化症疾病进展预后模型。

Praet, Jelle; Anderhalten, Lina; Comi, Giancarlo; Horakova, Dana; Ziemssen, Tjalf; Vermersch, Patrick; Lukas, Carsten; Van Leemput, Koen; Steppe, Marjan; Manero, Noemí; Kadas, Ella; Bernard, Alexis; van Rampelbergh, Jean; de Boer, Erik; Zingler, Vera; Smeets, Dirk; Ribbens, Annemie; Paul, Friedemann